Performance of Area under the Concentration-Time Curve Estimations of Vancomycin with Limited Sampling by a Newly Developed Web Application.
Adult
Anti-Bacterial Agents
/ administration & dosage
Area Under Curve
Blood Specimen Collection
/ methods
Drug Monitoring
/ methods
Female
Humans
Infusions, Intravenous
Internet
Male
Methicillin-Resistant Staphylococcus aureus
/ drug effects
Retrospective Studies
Software
Staphylococcal Infections
/ blood
Time Factors
Vancomycin
/ administration & dosage
area under the concentration-time curve
bayesian
software
therapeutic drug monitoring
vancomycin
Journal
Pharmaceutical research
ISSN: 1573-904X
Titre abrégé: Pharm Res
Pays: United States
ID NLM: 8406521
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
31
10
2020
accepted:
09
03
2021
pubmed:
31
3
2021
medline:
9
11
2021
entrez:
30
3
2021
Statut:
ppublish
Résumé
Therapeutic drug monitoring guided by the area under the concentration-time curve (AUC-guided TDM) is recommended for vancomycin. However, validated efficient software remains elusive to popularize AUC-guided TDM in Japan. The aim of this study was to validate a newly developed web application, PAT, for AUC estimation. PAT was developed on the R ver. 3.6.2 platform for use with mobile phones and personal computers. AUC estimated by PAT (AUC Investigating the best sampling points with limited sampling, PAT produced the least bias using two concentrations at 1 h and 11 h after the end of infusion (slope 1.18, intercept -15.57, median AUC The new application using two concentrations was appropriately validated and might be efficient in popularizing the AUC-guided TDM of vancomycin.
Identifiants
pubmed: 33782837
doi: 10.1007/s11095-021-03030-y
pii: 10.1007/s11095-021-03030-y
doi:
Substances chimiques
Anti-Bacterial Agents
0
Vancomycin
6Q205EH1VU
Types de publication
Journal Article
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
637-646Subventions
Organisme : Ministry of Education, Culture, Sports, Science and Technology
ID : 20K17467
Références
Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. J Rybak M, Talan DA, chambers HF; Infectious Diseases Society of America. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18–55. https://doi.org/10.1093/cid/ciq146 .
doi: 10.1093/cid/ciq146
pubmed: 21208910
Matsumoto K, Takesue Y, Ohmagari N, Mochizuki T, Mikamo H, Seki M, et al. Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Infect Chemother. 2013;19(3):365–80. https://doi.org/10.1007/s10156-013-0599-4 .
doi: 10.1007/s10156-013-0599-4
pubmed: 23673472
Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020;77(11):835–64. https://doi.org/10.1093/ajhp/zxaa036 .
doi: 10.1093/ajhp/zxaa036
pubmed: 32191793
Neely MN, Youn G, Jones B, Jelliffe RW, Drusano GL, Rodvold KA, et al. Are vancomycin trough concentrations adequate for optimal dosing? Antimicrob Agents Chemother. 2014;58(1):309–16. https://doi.org/10.1128/AAC.01653-13 .
doi: 10.1128/AAC.01653-13
pubmed: 24165176
pmcid: 3910745
Turner RB, Kojiro K, Shephard EA, Won R, Chang E, Chan D, et al. Review and validation of Bayesian dose-optimizing software and equations for calculation of the vancomycin area under the curve in critically ill patients. Pharmacotherapy. 2018;38(12):1174–83. https://doi.org/10.1002/phar.2191 .
doi: 10.1002/phar.2191
pubmed: 30362592
Kufel WD, Seabury RW, Mogle BT, Beccari MV, Probst LA, Steele JM. Readiness to implement vancomycin monitoring based on area under the concentration-time curve: a cross-sectional survey of a national health consortium. Am J Health Syst Pharm. 2019;76:889–94. https://doi.org/10.1093/ajhp/zxz070 .
doi: 10.1093/ajhp/zxz070
pubmed: 31063582
Yasuhara M, Iga T, Zenda H, Okumura K, Oguma T, Yano Y, et al. Population pharmacokinetics of vancomycin in Japanese adult patients. Ther Drug Monit. 1998;20(2):139–48. https://doi.org/10.1097/00007691-199804000-00003 .
doi: 10.1097/00007691-199804000-00003
pubmed: 9558127
Brown KM, Dennis JE. Derivative free analogues of the Levenberg–Marquardt and gauss algorithms for nonlinear least square approximations. Numer Math. 1972;18:289–97. https://doi.org/10.1007/BF01404679 .
doi: 10.1007/BF01404679
Nakashima M, Katagiri K, Oguma T. Phase I studies on vancomycin hydrochloride for infection. Chemotherapy. 1992;40(2):210–24. https://doi.org/10.11250/chemotherapy1953.40.210 .
doi: 10.11250/chemotherapy1953.40.210
Oda K, Kasada T, Yoshikawa M, Tanoue M, Yamashita T, Takeshita Y. Therapeutic drug monitoring based on early measurements of serum teicoplanin levels in Japanese patients. Ther Drug Monit. 2014;36(3):401–5. https://doi.org/10.1097/FTD.0000000000000002 .
doi: 10.1097/FTD.0000000000000002
pubmed: 24270046
Kobayashi M, Kogure A, Uchiyama H, Tachiki H, Ueno K. A questionnaire evaluation of new vancomycin TDM software; TOWA-TDM (VCM). Igaku to Yakugaku. 2020;77(4):587–95.
Sano K, Suzuki N, Saitoh M. Performance of various pharmacokinetic parameters in predicting vancomycin serum concentrations. Jpn J Pharm Health Care Sci. 2008;34(1):1–12. https://doi.org/10.5649/jjphcs.34.1 .
doi: 10.5649/jjphcs.34.1
Komoto A, Maiguma T, Teshima D, Sugiyama T, Haruki Y. Effects of pharmacist intervention in vancomycin treatment for patients with bacteremia due to methicillin-resistant Staphylococcus aureus. PLoS One. 2018;13(9):e0203453. https://doi.org/10.1371/journal.pone.0203453 .
doi: 10.1371/journal.pone.0203453
pubmed: 30188918
pmcid: 6126860
Takenaka T, Watanabe T, Hayashi T, Hata K, Ono N, Kumon H, et al. Pharmacokinetics of vancomycin and dosage planning in patients with renal insufficiency. Chemotherapy. 1993;41(10):1079–89. https://doi.org/10.11250/chemotherapy1953.41.1079 .
doi: 10.11250/chemotherapy1953.41.1079
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. https://doi.org/10.1159/000180580 .
doi: 10.1159/000180580
pubmed: 1244564
Neely MN, Kato L, Youn G, Kraler L, Bayard D, van Guilder M, et al. Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing. Antimicrob Agents Chemother. 2018;62(2):e02042–17. https://doi.org/10.1128/AAC.02042-17 .
doi: 10.1128/AAC.02042-17
pubmed: 29203493
pmcid: 5786789
Oda K, Jono H, Nosaka K, Saito H. Reduced nephrotoxicity with vancomycin therapeutic drug monitoring guided by area under the concentration-time curve against a trough 15–20 μg/mL concentration. Int J Antimicrob Agents. 2020;56(4):106109. https://doi.org/10.1016/j.ijantimicag.2020.106109 .
doi: 10.1016/j.ijantimicag.2020.106109
pubmed: 32721597
Meng L, Wong T, Huang S, Mui E, Nguyen V, Espinosa G, et al. Conversion from vancomycin trough concentration-guided dosing to area under the curve-guided dosing using two sample measurements in adults: implementation at an academic medical center. Pharmacotherapy. 2019;39(4):433–42. https://doi.org/10.1002/phar.2234 .
doi: 10.1002/phar.2234
pubmed: 30739349
Finch NA, Zasowski EJ, Murray KP, Mynatt RP, Zhao JJ, Yost R, et al. A quasi-experiment to study the impact of vancomycin area under the concentration-time curve-guided dosing on vancomycin-associated nephrotoxicity. Antimicrob Agents Chemother. 2017;61(12):e01293–17. https://doi.org/10.1128/AAC.01293-17 .
doi: 10.1128/AAC.01293-17
pubmed: 28923869
pmcid: 5700348
Suzuki Y, Kawasaki K, Sato Y, Tokimatsu I, Itoh H, Hiramatsu K, et al. Is peak concentration needed in therapeutic drug monitoring of vancomycin? A pharmacokinetic-pharmacodynamic analysis in patients with methicillin-resistant Staphylococcus aureus pneumonia. Chemotherapy. 2012;58(4):308–12. https://doi.org/10.1159/00034316 .
doi: 10.1159/00034316
pubmed: 23147106
Men P, Li HB, Zhai SD, Zhao RS. Association between the AUC0–24/MIC ratio of vancomycin and its clinical effectiveness: A systematic review and meta-analysis. PLoS One. 2016;11(1):e0146224. https://doi.org/10.1371/journal.pone.0146224 .
doi: 10.1371/journal.pone.0146224
pubmed: 26731739
pmcid: 4701440
Clark L, Skrupky LP, Servais R, Brummitt CF, Dilworth TJ. Examining the relationship between vancomycin area under the concentration-time curve and serum trough levels in adults with presumed or documented staphylococcal infections. Ther Drug Monit. 2019;41(4):483–8. https://doi.org/10.1097/FTD.0000000000000622 .
doi: 10.1097/FTD.0000000000000622
pubmed: 30817704
Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. A pharmacokinetic analysis program (multi) for microcomputer. Aust J Pharm. 1981;4(11):879–85. https://doi.org/10.1248/bpb1978.4.879 .
doi: 10.1248/bpb1978.4.879
Levey AS, Perrone RD, Madias NE. Serum creatinine and renal function. Annu Rev Med. 1988;39:465–90. https://doi.org/10.1146/annurev.me.39.020188.002341 .
doi: 10.1146/annurev.me.39.020188.002341
pubmed: 3285786
Tanaka A, Suemaru K, Otsuka T, Ido K, Nishimiya T, Sakai I, et al. Estimation of the initial dose setting of vancomycin therapy with use of cystatin C as a new marker of renal function. Ther Drug Monit. 2007;29(2):261–4. https://doi.org/10.1097/FTD.0b013e31803bcfd2 .
doi: 10.1097/FTD.0b013e31803bcfd2
pubmed: 17417082